Copy
View this email in your browser

What's new in HSCI research

Bioartificial device offers potential for treatment of Type 1 diabetes

A Harvard Stem Cell Institute (HSCI) led collaboration developed a bioartificial pancreas, which offers the potential for faster, more effective treatment of Type 1 diabetes.
  • What they did: Developed a new kind of macroencapsulation device to protect the insulin-producing cells in the pancreas.
  • What they found: This new device offers protection from the immune system while allowing cell nutrients to pass through.
  • Why it matters: This convection-enhanced macroencapsulation device offers the possibility of better treatment for the more than 40 million worldwide who suffer from Type 1 diabetes.

A new signaling system for blood regeneration

A group of researchers, led by HSCI Co-Director David Scadden, MD, have shown that bone cells pass packets of genetic material directly to bone progenitors.
  • What they did: Observed a direct process for spurring bone cell production that had been seen in cultures but not in the human body.
  • What they found: Vesicles from bone cells can pass material directly to bone progenitors, independent of hormone (cytokine) intervention.
  • Why it matters: This alternative means of spurring blood cell production sheds light on the human body’s ability to increase immune cells and fight infection.
Browse all HSCI news stories
Twitter
Facebook
Website
Copyright © 2021 Harvard Stem Cell Institute, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.